Benitec's BB-401 misses Stage 1 response threshold in Phase II for head and neck cancer

Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) said an initial analysis of the 12-patient Stage 1 cohort in a Phase II trial to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed that once-weekly intratumoral injections of BB-401 did not produce the objective response rate (ORR) required to support continued enrollment in the trial. The company said it will continue patient-follow-up and disclose detailed data following completion of additional analyses...